Exhibit 10.1
November 4, 2026
Sam Jackson, M.D.
451 Kansas Street, #466
San Francisco, California 94107
| Re: | Offer of Employment — Chief Medical Officer |
Dear Sam:
NervGen US Inc. (the “Company”), a wholly owned subsidiary of NervGen Pharma Corp. (the “Parent”), is pleased to offer you employment as Chief Medical Officer on the terms set out in this letter (this “Offer Letter”). This offer is subject to approval by the Board of Directors of the Parent (the “Board”) or its Compensation Committee (the “Committee”), and this Offer Letter will become effective only upon that approval and its execution by both you and the Company. This Offer Letter, together with the Sign-On Bonus Agreement attached as Exhibit A (the “Sign-On Bonus Agreement”) and the other agreements referred to below, sets out the complete terms of your employment and supersedes all prior discussions, correspondence, term sheets, and offers, whether written or oral, relating to your employment.
| 1. | Position and Duties. You will serve as Chief Medical Officer of the Company and, as part of your duties to the Company, as Chief Medical Officer of the Parent, reporting directly to the Chief Executive Officer. You will be responsible for the Company’s clinical development strategy and medical function, including medical oversight of the NVG-291 program and the Company’s Phase 3 RESTORE study (Protocol NVG-291-301) (the “RESTORE Study”), clinical safety and pharmacovigilance, and the medical aspects of the Company’s interactions with regulatory authorities, together with such other duties consistent with your position as the Chief Executive Officer may assign from time to time. The compensation and benefits provided under this Offer Letter fully compensate you for all services you perform for the Parent and any other affiliate of the Company. You acknowledge that the Board may designate you as an executive officer of the Parent for purposes of applicable U.S. and Canadian securities laws, and you agree to cooperate with any filings or reports required as a result. |
You agree to devote your full business time, attention, and best efforts to the Company and to comply with all policies of the Company and the Parent as in effect from time to time, including the Code of Business Conduct and Ethics, the Insider Trading Policy, and the Compensation Recovery Policy described in Section 13. You may, without violating this Offer Letter, (a) maintain your medical license and board certification, (b) participate in academic, professional society, and charitable activities, and (c) with the prior written consent of the Board, serve on the board of directors of one for-profit company, in each case only so long as such activities do not, individually or in the aggregate, interfere with the performance of your duties, create an actual or potential conflict of interest, or involve any business that competes with the Company or the Parent. Any clinical practice requires the prior written consent of the Chief Executive Officer.
Page 1
| 2. | Start Date; Conditions. Your employment will commence on November 30, 2026, or such other date as you and the Chief Executive Officer agree in writing, which shall be no later than December 7, 2026 (the date your employment actually commences, the “Start Date”). This offer is contingent upon (a) approval by the Board or the Committee, (b) verification of your identity and authorization to work in the United States, (c) satisfactory completion of a background check conducted in accordance with applicable law, including the California Fair Chance Act (California Government Code Section 12952) and the California Investigative Consumer Reporting Agencies Act, and including verification of your medical licensure history and screening against the FDA Debarment List, the HHS-OIG List of Excluded Individuals/Entities, and the FDA list of disqualified clinical investigators, and (d) your execution of the Confidential Information and Invention Assignment Agreement described in Section 16. |
| 3. | Work Location. Your principal place of work will be your home office in San Francisco, California. You will travel as reasonably required by your duties, including to the Company’s offices, clinical trial sites, regulatory meetings, and meetings of the Board. |
| 4. | Base Salary. Your initial base salary will be $525,000 per year (as in effect from time to time, “Base Salary”), payable in accordance with the Company’s regular payroll practices and subject to applicable withholdings. Your position is classified as exempt from the overtime requirements of federal and California law. The Committee will review your Base Salary annually and may increase it in its discretion. Your Base Salary may not be reduced except as part of an across-the-board reduction of not more than ten percent (10%) that applies proportionately to all of the Parent’s executive officers. |
| 5. | Annual Incentive Bonus. Beginning with fiscal year 2027, you will be eligible for an annual incentive bonus with a target opportunity equal to 40% of your Base Salary (the “Target Bonus”), based on the achievement of Company and individual performance objectives established by the Committee. The Committee will determine whether, and the extent to which, the applicable objectives have been achieved and the amount of any bonus, which may be more or less than the Target Bonus. Any annual bonus will be paid when bonuses are paid to the Company’s other executives, and in no event later than March 15 of the year following the year to which the bonus relates, and, except as provided in Section 10, you must be employed on the payment date to earn it. You will not be eligible for an annual bonus for fiscal year 2026; the Sign-On Bonus is provided in lieu of any 2026 bonus. |
| 6. | Sign-On Bonus. You will be eligible for a sign-on bonus of $208,000 (the “Sign-On Bonus”), payable in two installments, $100,000 after your Start Date and the remaining $108,000 on or after March 31, 2027. The terms of the Sign-On Bonus, including the conditions to payment and the deadlines for payment, are governed exclusively by the Sign-On Bonus Agreement, which is a separate agreement from this Offer Letter and must be separately signed. Neither installment is conditioned on the achievement of any enrollment, clinical, or other performance milestone. |
Page 2
| 7. | Equity Awards. |
| (a) | Initial Option. Subject to approval by the Board or the Committee, the Parent will grant you an option to purchase 1,156,135 common shares of the Parent (the “Initial Option”). The Initial Option will be granted on the first date on or after the Start Date on which the Board or the Committee acts to approve it and that falls within an open trading window under the Parent’s Insider Trading Policy (the “Grant Date”). The exercise price per share will equal the closing price of the Parent’s common shares on the Nasdaq Capital Market on the Grant Date, and in no event will it be less than the fair market value of a common share on the Grant Date determined in accordance with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”). The Initial Option will have a term of ten (10) years, subject to earlier termination as provided in the applicable plan and award agreement. Twenty-five percent (25%) of the shares subject to the Initial Option will vest on the first anniversary of the Start Date, and the remaining seventy-five percent (75%) will vest in thirty-six (36) substantially equal monthly installments thereafter, in each case subject to your continuous service through the applicable vesting date. The Initial Option is intended to qualify as an incentive stock option under Section 422 of the Code to the maximum extent permitted, and any portion that does not so qualify will be a non-qualified stock option. |
| (b) | Milestone RSUs. Subject to approval by the Board or the Committee, on the Grant Date the Parent will grant you 50,000 restricted share units (the “Milestone RSUs”), each representing the right to receive one common share of the Parent upon vesting. The Milestone RSUs will vest in full if, and only if, (i) the Enrollment Milestone is achieved on or before August 1, 2027 and (ii) you remain in continuous service with the Company through the date on which the Committee certifies its achievement (the “Certification Date”). The “Enrollment Milestone” means the randomization and enrollment of at least one hundred fifty (150) participants in the RESTORE Study, as determined by the Committee in good faith on the basis of the Company’s clinical trial records. The Committee will make its determination within thirty (30) days after the Enrollment Milestone is achieved. If the RESTORE Study protocol is amended to change its target enrollment, the Committee may in good faith equitably adjust the participant threshold. Vested Milestone RSUs will be settled in common shares within thirty (30) days after the Certification Date and in no event later than March 15 of the year following the year in which they vest. If the Enrollment Milestone is not achieved on or before August 1, 2027, the Milestone RSUs will be forfeited automatically on that date without consideration. The Milestone RSUs will not vest by reason of a Change in Control, a termination of your employment, or any other event except as the Committee may determine in its discretion. |
| (c) | General Terms. The Initial Option and the Milestone RSUs (together, the “Initial Awards”) will be granted under, and governed by, the Parent’s equity incentive plan as in effect on the Grant Date (the “Plan”) and the Parent’s standard forms of award agreement, except as expressly provided in this Offer Letter. If the Plan does not have sufficient shares available for all or any portion of the Initial Awards, the Parent may grant that portion as an inducement award outside the Plan in accordance with Nasdaq Listing Rule 5635(c)(4), on terms otherwise substantially identical to those that would have applied under the Plan, in which case any option so granted will be a non-qualified stock option. The number of shares subject to the Initial Awards is fixed and will be adjusted only as provided in the Plan for share splits, consolidations, and similar changes in capitalization; it will not be adjusted by reference to any percentage of the Parent’s outstanding shares. Neither the Company nor the Parent makes any representation regarding the tax treatment of the Initial Awards, and you are encouraged to consult your own tax advisor. You will be eligible for additional equity awards at the discretion of the Board or the Committee. |
Page 3
| 8. | Benefits, Time Off, and Expenses. You will be eligible to participate in the employee benefit plans made available by the Company to its senior executives, including its group health and 401(k) plans, subject to the terms of the applicable plan documents, which the Company may amend or terminate at any time. You will be eligible for paid time off under the Company’s flexible time off policy for senior executives, and for paid sick leave in accordance with the California Healthy Workplaces, Healthy Families Act of 2014 (California Labor Code Section 245 et seq.). Because the flexible time off policy does not provide for the accrual of vacation, no vacation pay will be due upon termination, except to the extent the Company has provided for accrued vacation under any other policy, in which case vested vacation will be paid in accordance with California Labor Code Section 227.3. The Company will reimburse you, in accordance with California Labor Code Section 2802, for all necessary and reasonable business expenses incurred in performing your duties, including the costs of maintaining your medical license and board certification and reasonable professional society dues, in accordance with the Company’s expense reimbursement policies. |
| 9. | Indemnification and D&O Insurance. The Company and the Parent will enter into their standard form of indemnity agreement with you, and you will be covered under the Parent’s directors’ and officers’ liability insurance policy on the same basis as the Parent’s other executive officers, both during your employment and thereafter with respect to acts and omissions during your employment. |
| 10. | At-Will Employment; Termination; Severance. |
| (a) | At-Will Employment. Your employment is at will, meaning that either you or the Company may terminate it at any time, with or without Cause or notice, subject only to the severance provisions of this Section 10. Nothing in this Offer Letter creates employment for any definite term. Your at-will status may be modified only by a written agreement signed by you and the Chief Executive Officer and approved by the Committee. |
| (b) | Accrued Obligations. Upon any termination of your employment, the Company will pay or provide (i) your earned but unpaid Base Salary through the termination date, (ii) any applicable accrued benefits to the extent required by applicable law, (iii) unreimbursed business expenses properly incurred, and (iv) any vested benefits under the Company’s benefit plans in accordance with their terms (together, the “Accrued Obligations”). |
| (c) | Qualifying Termination Outside a Change in Control Period. If the Company terminates your employment without Cause (other than by reason of your death or Disability) or you resign for Good Reason (either, a “Qualifying Termination”), in either case outside a Change in Control Period, then, subject to Section 10(e), the Company will (i) continue to pay your Base Salary for nine (9) months following the termination date in accordance with its regular payroll practices, (ii) pay any annual bonus for the fiscal year preceding the year of termination that the Committee has determined to be earned but that remains unpaid, at the time it would otherwise have been paid, and (iii), if you timely elect continuation coverage under COBRA, pay the employer portion of the premiums for you and your covered dependents, at the rate in effect for active employees, until the earliest of (A) nine (9) months following the termination date, (B) the date you become eligible for group health coverage through another employer, and (C) the date your COBRA rights end. If the Company determines that it cannot provide the COBRA benefit without violating applicable law or incurring penalties, it will instead pay you a taxable monthly amount equal to the employer portion of the premium for the remainder of that period. |
Page 4
| (d) | Qualifying Termination During a Change in Control Period. If you experience a Qualifying Termination during a Change in Control Period, then, subject to Section 10(e) and in lieu of the benefits under Section 10(c), the Company will (i) pay you a lump sum equal to the sum of twelve (12) months of your Base Salary and one hundred percent (100%) of your Target Bonus for the year of termination, (ii) pay any earned but unpaid prior-year bonus as described in Section 10(c)(ii), (iii) provide the COBRA benefit described in Section 10(c) for up to twelve (12) months, and (iv) cause all of your then-outstanding and unvested equity awards that vest solely on the basis of continued service, including the Initial Option, to vest in full. Awards subject to performance-based vesting, including the Milestone RSUs, will be treated as provided in the applicable award agreement and Section 7(b). If a Qualifying Termination occurs within the three (3) months before a Change in Control, your unvested service-based awards will remain outstanding (but will not vest) for three (3) months following the termination date so that the acceleration in clause (iv) may take effect if a Change in Control occurs during that period, and they will be forfeited if no Change in Control occurs. The lump sum in clause (i) will be paid within sixty (60) days after the later of the termination date and the Change in Control, subject to Section 10(e). |
| (e) | Release. Your receipt of any benefit under Section 10(c) or 10(d) (other than the Accrued Obligations) is conditioned on (i) your execution of a separation agreement and general release of all claims that may lawfully be released, including a waiver under California Civil Code Section 1542, in favor of the Company, the Parent, and their affiliates in a form provided by the Company, which becomes effective and irrevocable within sixty (60) days after the termination date, (ii) your return of all Company property, (iii) your resignation from all offices and positions with the Company, the Parent, and their affiliates, and (iv) your continued compliance with your obligations under the Confidential Information and Invention Assignment Agreement. Payments will begin on the first regular payroll date after the release becomes effective, and the first payment will include any amounts that would otherwise have been paid before that date; provided that if the sixty-day period spans two calendar years, payments will begin in the second year. |
| (f) | Death or Disability. Your employment will terminate automatically upon your death, and the Company may terminate it upon your Disability. In either case, you or your estate will receive the Accrued Obligations and any earned but unpaid prior-year bonus. “Disability” means your inability, due to a physical or mental impairment, to perform the essential functions of your position, with or without reasonable accommodation, for one hundred twenty (120) consecutive days or one hundred eighty (180) days in any twelve-month period, determined in accordance with applicable law. |
| (g) | Exclusive Remedy. The payments and benefits provided under this Section 10 are the only payments and benefits to which you will be entitled in connection with the termination of your employment, and they are in lieu of any severance or similar benefits under any plan, policy, or practice of the Company or the Parent. |
| (h) | No Duty to Mitigate. You shall have no duty to mitigate damages upon a Qualifying Termination by seeking new employment or otherwise. |
Page 5
| 11. | Definitions. For purposes of this Offer Letter: |
| (a) | “Cause” means your (i) conviction of, or plea of guilty or no contest to, any felony or any crime involving fraud, dishonesty, or moral turpitude; (ii) commission of any act of fraud, embezzlement, or misappropriation against the Company or the Parent; (iii) willful misconduct or gross negligence that is, or is reasonably likely to be, materially injurious to the Company or the Parent; (iv) material breach of this Offer Letter, the Confidential Information and Invention Assignment Agreement, or any material written policy of the Company or the Parent, including the Insider Trading Policy and the Code of Business Conduct and Ethics; (v) willful failure to perform your material duties or to follow a lawful directive of the Chief Executive Officer or the Board; or (vi) debarment under 21 U.S.C. § 335a, exclusion from any federal health care program, disqualification by the FDA or any comparable authority as a clinical investigator, suspension or revocation of any medical license you hold on disciplinary grounds (it being understood that the voluntary lapse, inactivation, or non-renewal of your medical license will not constitute Cause), or a finding of research misconduct by any governmental authority or institution. Before the Company may terminate your employment for Cause under clause (iv) or (v), it will give you written notice describing the conduct and, if the conduct is reasonably capable of cure, thirty (30) days to cure it. No act or failure to act will be considered “willful” if done or omitted in good faith and with a reasonable belief that it was in the best interests of the Company. |
| (b) | “Good Reason” means the occurrence of any of the following without your written consent: (i) a reduction in your Base Salary other than an across-the-board reduction permitted by Section 4; (ii) a material diminution in your authority, duties, or responsibilities, provided that following a Change in Control it will not constitute Good Reason solely that the Parent has become a subsidiary or business unit of a larger organization, so long as you continue to lead clinical development for the NVG-291 program and any other clinical programs initiated at the Company prior to the Change in Control that the Parent or its successor continues to develop; (iii) a requirement that you relocate your principal place of work by more than fifty (50) miles; (iv) a change in your reporting relationship such that you are no longer reporting directly to the Chief Executive Officer of the Parent, provided that following a Change in Control it will not constitute Good Reason so long as you report to the Chief Executive Officer (or equivalent senior-most officer) of the Parent or of the subsidiary or business unit that carries on the Parent’s business; or (v) a material breach of this Offer Letter by the Company. A resignation will be for Good Reason only if you give the Company written notice describing the condition within sixty (60) days after it first occurs, the Company fails to cure the condition within thirty (30) days after receiving the notice, and you resign within thirty (30) days after the end of that cure period. |
Page 6
| (c) | “Change in Control” has the meaning given in the Plan, provided that, to the extent necessary to avoid adverse taxation under Section 409A of the Code, no event will constitute a Change in Control unless it is also a “change in control event” within the meaning of Treasury Regulation Section 1.409A-3(i)(5). |
| (d) | “Change in Control Period” means the period beginning three (3) months before, and ending twelve (12) months after, the consummation of a Change in Control. |
| 12. | Section 280G. If any payment or benefit you would receive in connection with a change in control would constitute a “parachute payment” within the meaning of Section 280G of the Code and would be subject to the excise tax imposed by Section 4999 of the Code, then those payments and benefits will be either delivered in full or reduced to the extent necessary so that no portion is subject to the excise tax, whichever results in your receipt, on an after-tax basis, of the greater amount. Any reduction will be made in the manner that results in the greatest economic benefit to you and, to the extent economically equivalent, in reverse chronological order, and in all events in a manner that complies with Section 409A of the Code. The determinations under this Section 12 will be made by a nationally recognized accounting firm selected and paid for by the Company. |
| 13. | Compensation Recovery. All incentive-based compensation paid or awarded to you, including annual bonuses and equity awards, is subject to recovery under the Parent’s Compensation Recovery Policy adopted pursuant to Rule 10D-1 under the Securities Exchange Act of 1934 and Nasdaq Listing Rule 5608, as amended from time to time, and to any other recovery required by applicable law or listing standards. No recovery under such policy or law will constitute Good Reason or a breach of this Offer Letter. |
| 14. | Section 409A. The payments and benefits under this Offer Letter are intended to be exempt from, or to comply with, Section 409A of the Code and the regulations and guidance thereunder (“Section 409A”), and this Offer Letter will be interpreted accordingly. Each installment payment is a separate payment for purposes of Section 409A. Any reference to a termination of employment means a “separation from service” within the meaning of Section 409A. If you are a “specified employee” on the date of your separation from service, any payment of nonqualified deferred compensation that would otherwise be paid within six (6) months after that date will instead be paid on the first business day after the six-month period (or, if earlier, upon your death). Reimbursements will be paid no later than the end of the year following the year in which the expense was incurred, the amount eligible for reimbursement in one year will not affect the amount eligible in any other year, and the right to reimbursement is not subject to liquidation or exchange for another benefit. |
| 15. | Your Representations. You represent that (a) you are not party to any agreement or subject to any obligation, including any non-competition, non-solicitation, or confidentiality obligation to a current or former employer, that would prevent or restrict you from accepting this offer or fully performing your duties, and you have provided the Company with copies of any agreement containing such obligations; (b) you will not bring to the Company or use in your work any confidential or proprietary information or materials of any current or former employer or other third party; (c) you have never been debarred under 21 U.S.C. § 335a, excluded from any federal health care program, or disqualified or restricted as a clinical investigator, and no such proceeding is pending or, to your knowledge, threatened against you; and (d) no medical license you hold or have held has been the subject of any disciplinary action. You will notify the Company immediately if any of these representations ceases to be true during your employment. |
Page 7
| 16. | Confidential Information and Invention Assignment Agreement. As a condition of your employment, you must sign the Company’s Confidential Information and Invention Assignment Agreement in the form provided to you (the “CIIA”). |
| 17. | Securities Law Matters. You acknowledge that the Parent’s common shares are listed on the Nasdaq Capital Market and that the Parent is a reporting issuer under Canadian securities laws. As an executive officer, you may be subject to insider reporting obligations and trading restrictions under U.S. and Canadian securities laws and the Parent’s policies, and you agree to comply with them. You further acknowledge that neither the Company nor the Parent, nor any of their directors, officers, or representatives, has made any representation or promise to you regarding the future value or trading price of the Parent’s common shares, the likelihood or timing of any clinical, regulatory, or commercial outcome, or the prospects of NVG-291 or any other product candidate, and that you have not relied on any such statement in accepting this offer. |
| 18. | Protected Rights. Nothing in this Offer Letter, the Sign-On Bonus Agreement, or the CIIA prohibits or restricts you from filing a charge or complaint with, communicating with, providing information to, or participating in any investigation or proceeding conducted by the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the California Civil Rights Department, the National Labor Relations Board, any Canadian securities regulatory authority, or any other governmental agency, from receiving an award for information provided to any governmental agency, or from exercising any rights you may have under Section 7 of the National Labor Relations Act or California Labor Code Sections 232, 232.5, or 1102.5, including disclosing your wages or discussing your working conditions. Nothing in this Offer Letter, the Sign-On Bonus Agreement, or the CIIA prevents you from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that you have reason to believe is unlawful. |
| 19. | Miscellaneous. This Offer Letter will be governed by the laws of the State of California, without regard to its conflict-of-laws principles, and the state and federal courts located in the State of California will have exclusive jurisdiction over any dispute arising out of it. All payments under this Offer Letter are subject to applicable withholding. This Offer Letter may be amended only by a written instrument signed by you and the Chief Executive Officer and approved by the Committee. The Company may assign this Offer Letter to the Parent, to any affiliate, or to any successor to all or substantially all of its business or assets, and will require any such successor to assume it; you may not assign it. If any provision of this Offer Letter is held invalid or unenforceable, the remaining provisions will remain in full force and effect. This Offer Letter, together with the Sign-On Bonus Agreement, the CIIA, the indemnity agreement, and the award agreements for the Initial Awards, constitutes the entire agreement between you and the Company regarding its subject matter. This Offer Letter may be executed in counterparts, including by electronic signature, each of which will be deemed an original. |
Page 8
This offer will remain open until 5:00 p.m. Eastern Time on November 16, 2026. If you agree with these terms, please sign and return this Offer Letter and the Sign-On Bonus Agreement to me. We are delighted at the prospect of you joining NervGen and look forward to working with you.
| Sincerely, | ||
| NERVGEN US INC. | ||
| By: | /s/ Adam Rogers | |
| Name: | Adam Rogers, M.D. | |
| Title: | Chief Executive Officer | |
| Date: | November 16, 2026 | |
Acknowledged and agreed by NervGen Pharma Corp. as to Sections 1, 7, 9, and 13:
| NERVGEN PHARMA CORP. | ||
| By: | /s/ Keith Vendola | |
| Name: | Keith Vendola, M.D., M.B.A. | |
| Title: | Chief Financial Officer | |
| Date: | November 16, 2026 | |
| Agreed and accepted: | ||
| /s/ Sam Jackson | ||
| Sam Jackson, M.D. | ||
| Date: November 16, 2026 | ||
Page 9
EXHIBIT A
SIGN-ON BONUS AGREEMENT
This Sign-On Bonus Agreement (this “Agreement”) is entered into as of the date last signed below by and between NervGen US Inc. (the “Company”) and Sam Jackson, M.D. (“you”). This Agreement is separate from, and is not part of, the offer letter between you and the Company dated November 4, 2026 (the “Offer Letter”). Capitalized terms used but not defined in this Agreement have the meanings given in the Offer Letter.
| 1. | Sign-On Bonus. Subject to the terms of this Agreement, the Company will pay you a one-time sign-on bonus of $208,000 (the “Sign-On Bonus”) in two installments. The first installment of $100,000 (the “First Installment”) will be paid on the Company’s first regular payroll date following the Start Date. The second installment of $108,000 (the “Second Installment”) will be paid on the Company’s first regular payroll date on or after March 31, 2027, provided that you remain employed by the Company on March 31, 2027. If you experience a Qualifying Termination before March 31, 2027, the Second Installment will instead be paid in a lump sum, in addition to your severance benefits under Section 10 of the Offer Letter and subject to the same release condition, within sixty (60) days after the termination date; provided that if the sixty-day period spans two calendar years, payment will be made in the second year. If, before March 31, 2027, you resign from employment with the Company other than for Good Reason, or the Company terminates your employment for Cause, you will forfeit the Second Installment in its entirety, no portion of the Second Installment will be earned or payable, and the Company will have no further payment obligation to you under this Agreement. Once paid, neither installment is subject to repayment, except as provided in Section 2. Neither installment is conditioned on the achievement of any enrollment, clinical, or other performance milestone. The Sign-On Bonus is not compensation for purposes of any benefit plan of the Company or the Parent. |
| 2. | Purpose; Offset. The Sign-On Bonus is provided to compensate you for the annual bonus for 2026 that you will forfeit under your current employment arrangement by joining the Company (the “Forfeited Bonus”). If your current employer pays you any portion of the Forfeited Bonus, either before or after your separation from that employer, you will notify the Company promptly, the Second Installment will be reduced by the amount so paid, and, to the extent that amount exceeds the unpaid Second Installment, you will repay the excess to the Company within thirty (30) days. |
| 3. | Right to Consult an Attorney. In accordance with California Business and Professions Code Section 16608 and California Labor Code Section 926, you are hereby notified that you have the right to consult with an attorney of your choosing regarding this Agreement, and you acknowledge that you have been given at least five (5) business days to do so before signing it. This Agreement is intended to satisfy the requirements of those sections for a discretionary sign-on payment, and it will be interpreted accordingly. |
| 4. | General. All payments under this Agreement are subject to applicable withholding. This Agreement is governed by the laws of the State of California. Nothing in this Agreement alters the at-will nature of your employment. This Agreement constitutes the entire agreement between you and the Company regarding the Sign-On Bonus and may be amended only by a written instrument signed by you and the Chief Executive Officer. This Agreement may be executed in counterparts, including by electronic signature. |
Page 10
| NERVGEN US INC. | ||
| By: | /s/ Adam Rogers | |
| Name: | Adam Rogers, M.D. | |
| Title: | Chief Executive Officer | |
| Date: | November 16, 2026 | |
| /s/ Sam Jackson | ||
| Sam Jackson, M.D. | ||
| Date: November 16, 2026 | ||
Page 11